What should be normal BP in relation with age n when to start treatment ?
Reading File
Quick answer
Blood Pressure by Age and When to Start Treatment
Normal BP ranges
Current guidelines (ACC/AHA 2017, similarly ESC/ESH) use fixed categories for adults, not sliding age-based targets:
| Category | Systolic (mmHg) | Diastolic (mmHg) |
|---|---|---|
| Normal | <120 | and <80 |
| Elevated | 120-129 | and <80 |
| Stage 1 Hypertension | 130-139 | or 80-89 |
| Stage 2 Hypertension | ≥140 | or ≥90 |
| Hypertensive crisis | >180 | and/or >120 |
Older guidance (JNC 7) used 120/80 as normal and 140/90 as the hypertension cutoff - this is still commonly referenced in practice and by many labs.
By age group (approximate, for context):
- Children/adolescents: normal BP is defined by percentiles for age, sex, and height (not fixed numbers) - typically well below 120/80.
- Adults <65 years: normal is <120/80 mmHg.
- Older adults (≥65, especially ≥80): numeric "normal" is the same, but treatment targets are often relaxed (see below) because of frailty, orthostasis, and fall risk.
When to start treatment
This depends on BP stage plus overall cardiovascular (CV) risk, not age alone:
-
Elevated BP (120-129/<80): lifestyle changes only (weight loss, DASH diet, sodium restriction, exercise, alcohol moderation) - no medication.
-
Stage 1 (130-139/80-89):
- Start medication only if the patient has known cardiovascular disease, diabetes, chronic kidney disease, or a 10-year ASCVD risk score ≥10%.
- If no such risk factors, try lifestyle changes for 3-6 months first, then reassess.
-
Stage 2 (≥140/90): Start antihypertensive medication for everyone, regardless of other risk factors, usually with two drugs from different classes if BP is well above goal.
-
Hypertensive crisis (>180/120): Immediate treatment - urgent (oral, same-day) if no organ damage, emergent (IV, ICU) if there is organ damage (encephalopathy, MI, aortic dissection, etc.).
Age-specific treatment targets
- Under 65, generally healthy: target <130/80 mmHg.
- 65 and older (community-dwelling, ambulatory): target <130/80 mmHg is also now generally recommended, but individualized based on frailty and comorbidity burden.
- Elderly with high frailty burden, limited life expectancy, or symptomatic orthostatic hypotension: a more relaxed target (e.g., <150/90) may be reasonable to avoid falls and adverse drug effects.
- Diabetes or CKD: target <130/80 regardless of age.
- Pregnancy: treatment thresholds are different and lower (treatment often starts around 140/90, with tighter control for those with comorbidities) - this is a distinct clinical context from general adult hypertension.
Bottom line: There isn't really a separate "normal BP number" for each decade of adult life - 120/80 is the reference point across adulthood. What changes with age is the treatment threshold and target, largely because of how frailty, comorbidities, and drug tolerance shift risk-benefit calculations in older patients.
If you want, I can pull up the specific textbook/guideline sections (e.g., ACC/AHA 2017 or ESC/ESH 2018) with more detail or pediatric percentile tables - just let me know.
What antihypertensive drugs are first-line for different patient types?
Finding Sources
Finding Sources
Searching PubMed
hypertension first-line antihypertensive treatment guideline
Searching the Web
first-line antihypertensive drugs by patient type 2024 2025 guideline black patients diabetes CKD pregnancy
Quick answer
First-Line Antihypertensive Drugs by Patient Type
The overall first-line drug classes for hypertension are thiazide/thiazide-like diuretics, ACE inhibitors (ACEi), angiotensin receptor blockers (ARBs), and long-acting dihydropyridine calcium channel blockers (CCBs). Beta-blockers are no longer considered first-line for uncomplicated hypertension (reserved for specific indications like heart failure, post-MI, or arrhythmia). Choice among the four main classes is now individualized by comorbidity rather than by race, per the updated 2025 ACC/AHA guideline, which removed the older race-based recommendation that had favored CCBs/thiazides in Black patients (- StatPearls Antihypertensive Medications; Pharmacy Times, 2025 guideline overview).
By patient type
General/uncomplicated hypertension
- Any of the four first-line classes (thiazide-type diuretic, CCB, ACEi, or ARB) is acceptable as monotherapy.
- Stage 2 hypertension: start with two first-line agents from different classes, ideally as a single-pill combination.
Diabetes
- ACE inhibitor or ARB is preferred, especially if albuminuria is present, for both cardiovascular and kidney protection (- Goldman-Cecil Medicine).
- A CCB is a common add-on; the ACCOMPLISH trial supports ACEi + CCB (amlodipine) as an effective first-line combination (- Textbook of Family Medicine, 9e).
Chronic kidney disease (CKD), especially with albuminuria ≥30 mg/g or eGFR <60
- ACEi or ARB is first-line to slow progression of kidney disease and reduce cardiovascular risk. Do not combine ACEi and ARB together (increased hyperkalemia/renal failure risk).
- SBP goal is <130 mmHg in CKD per the 2025 AHA/ACC guideline.
Black patients
- Previously CCBs or thiazide-type diuretics were preferred. The 2025 ACC/AHA guideline has removed this race-based distinction; all four classes are now considered first-line, with selection based on individual comorbidities rather than race.
Elderly (including very old, ≥80)
- Thiazide-type diuretics and CCBs have strong trial support (e.g., HYVET in patients ≥80). Start at lower doses and titrate slowly, and individualize targets given fall/orthostasis risk.
Heart failure with reduced ejection fraction
- Not treated with the general first-line list. Guideline-directed therapy includes ACEi/ARB/ARNI, beta-blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors, which double as BP-lowering agents.
Pregnancy (or planning pregnancy)
- ACEi, ARBs, and direct renin inhibitors are contraindicated (teratogenic).
- Labetalol and extended-release nifedipine are the preferred first-line agents; methyldopa is an alternative but appears less effective than beta-blockers or CCBs at preventing severe hypertension (- 2025 AHA/ACC guideline).
Post-stroke / cerebrovascular disease
- ACEi/ARB or thiazide-type diuretics are generally favored based on outcome trial data, with individualized blood pressure targets to avoid overly rapid lowering in the acute phase.
Isolated systolic hypertension (common in older adults)
- CCBs and thiazide-type diuretics have the best trial evidence.
Combination principles
- Preferred combos: ACEi/ARB + CCB, or ACEi/ARB + thiazide-type diuretic (- Brenner and Rector's The Kidney; Textbook of Family Medicine).
- Avoid ACEi + ARB together.
- Avoid combining a beta-blocker with a non-dihydropyridine CCB (verapamil/diltiazem) due to bradycardia/heart block risk.
Recent evidence note
The 2025 ACC/AHA and 2025 Hypertension Canada guidelines (PMIDs 40419299, 40527605) and the 2024 ESH guideline (PMID 38914505) are the most current updates reflected above, including the removal of race-based drug selection and earlier CKD treatment initiation. A 2025 systematic review (PMID 41351601) also examined starting full-dose antihypertensives at diagnosis versus stepwise titration - if you want, I can pull details on that for the initial-dosing strategy question.
This is a shared conversation. Sign in to Orris to start your own chat.